MedTrace Logo

Microbiology and Treatment Outcome of Acute Exacerbation of Bronchiectasis in Hong Kong

NCT05112055 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2024-04-03

No results posted yet for this study

Summary

Bronchiectasis is a common disease worldwide with a high burden on healthcare resources. In Hong Kong (HK), local microbiological and clinical data regarding acute exacerbation of bronchiectasis (AEB) is lacking, in particular the frequency of pseudomonas aeruginosa (PA) in AEB is yet to be elucidated. A better understanding of the microbiology of AEB will provide evidence for judicious use of appropriate antibiotics in patients hospitalized for AEB to facilitate treatment and discharge.

This study aims to

1. elucidate the microbiology of AEB using both traditional culture and newer molecular multiplex methods,
2. identify factors associated with PA infection, and
3. describe the management and treatment outcome of AEB in HK

Conditions

Sponsors & Collaborators

  • Pamela Youde Nethersole Eastern Hospital

    lead OTHER

Principal Investigators

  • Charles Wong · Pamela Youde Nethersole Eastern Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-02
Primary Completion
2025-02-28
Completion
2025-12-01

Countries

  • Hong Kong

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05112055 on ClinicalTrials.gov